INMUNE BIO INC

INmune Bio secures an Australian R&D cash rebate to accelerate its oncology pipeline, boosting funding for key candidates like CORDStrom and XPro1595.

Inmune Bio: La Jolla‑based biotech on a cancer‑therapy mission, rising Nasdaq price, promising pipeline, and patient‑centric breakthroughs.

Inmune Bio Inc. seeks to transform cancer therapy with innovative oncology drugs, navigating biotech risks while partnering to accelerate clinical success.

Inmune Bio, a La Jolla‑based biotech, is advancing cancer immunotherapy with a focused pipeline, steady investor interest, and strategic collaborations for future growth.

Inmune Bio Inc. is poised to unveil top-line data from its Phase 2 MINDFuL trial in early Alzheimer’s Disease on June 30, 2025, with the company’s shares experiencing a 72% surge in pre-market trading ahead of the announcement.

Inmune Bio Inc., a clinical-stage biotech company, is focused on developing innovative cancer treatments and advancing its mission to bring new therapeutic options to patients.

Inmune Bio Inc, a clinical-stage biotech firm, faces significant financial and market challenges as it strives to develop groundbreaking cancer treatments, presenting a high-risk, high-reward scenario for investors.

Inmune Bio Inc, a clinical-stage biotech company, is at a critical juncture as it navigates the challenges of developing cancer treatments, with its financial performance and competitive landscape raising questions about its long-term success.

Inmune Bio Inc. is a clinical-stage biotech company dedicated to developing innovative cancer treatments, offering hope to patients and families affected by the disease.

Inmune Bio Inc. reported its first quarter 2025 results, with a focus on advancing its pipeline of cancer therapies and a market capitalization of approximately $173.53 million.